» Depomed Doses First Patient In New Phase 3 Clinical Trial Of Gabapentin GR In Postherpetic Neuralgia
Depomed, Inc. (NASDAQ:DEPO) announced that it has dosed the first patient in a new pivotal registration Phase 3 clinical trial designed to evaluate the safety and efficacy of Gabapentin GR™ for the…